The world of oncolytic virotherapies (OVs) is transforming cancer treatment, unlocking new levels of precision, immune activation, and therapeutic potential. However, with rapid advancements, fierce competition, and an ever-expanding pipeline, staying ahead requires more than just insights - it demands up-to-date intelligence, strategic foresight, and data-driven decision-making.
In 2024/25 alone, the oncology pipeline saw a surge of innovation, with 22 new OVs, over 105 drugs with events, and 654 total events spanning 368 total drug programs - a clear signal of the accelerating pace and complexity in this space.
Introducing the Oncolytic Virotherapies Analytical Tool - your comprehensive solution to navigate this dynamic field, track emerging trends, and capitalize on groundbreaking opportunities.
The Ultimate Tool for Exploring What Makes This Field So Exciting
- Tumor-selective replication - OVs are engineered to selectively infect and replicate in cancer cells while sparing normal tissue.
- Dual mechanism of action - 1. Direct oncolysis (destruction of tumor cells) 2. Indirect immune activation via release of tumor antigens and danger signals.
- Immune priming - Viral lysis converts “cold” tumors into “hot” ones by promoting immune cell infiltration and antigen presentation.
- Gene delivery vehicles - OVs can be engineered to express therapeutic genes (e.g., cytokines, immune checkpoint inhibitors, bispecific T-cell engagers).
- Synergy with other immunotherapies - Especially immune checkpoint inhibitors (ICIs), vaccines, and CAR-T therapies.
- Intratumoral administration - Allows for high local activity with potentially reduced systemic toxicity.
- Broad platform flexibility - Multiple virus families can be used (HSV, adenovirus, vaccinia, reovirus, measles, etc.), each with unique strengths.
The impact? A rapidly growing clinical pipeline, breakthrough FDA approvals, and a surge in investment opportunities - making the oncolytic virotherapy field one of the most exciting frontiers in oncology today.
6 Game-Changing Benefits for You
With the Oncolytic Virotherapies Analytical Tool you will:
- Track the Competitive Landscape - monitor active organizations, new drugs, targets, and technologies
- Accelerate Licensing & Partnerships - access top biotech developers, BD&L contacts, and academic projects
- Power High-Impact Reports & Presentations - fuel data-driven decisions with near real-time market intelligence - all exportable in ready made graphs and tables.
- Engage Key Opinion Leaders (KOLs) - connect with clinical and scientific experts shaping the field
- Find the Right Investors - tap into a network of oncology-focused funding partners
- Stay Ahead of Industry Events - analyze data from top global oncology conferences (AACR, ASCO, ESMO, ASH, and more)
Your Oncolytic Virotherapies Analytical Tool is never out of date thanks to continuous updates and monthly email alerts highlighting the latest developments in the field.
You will have thousands of drugs, targets, companies, clinical trials, deals and much more at your fingertips. See below for a breakdown of the near real-time coverage.
Support & Inspiration at Your Fingertips
Leverage expertise as your virtual business development team - ready when you are. The 24/7 support ensures help is always available, while a rich library of How-to Training Videos empowers you with proven best practices. From competitive pipeline analysis to real-world case studies submitted by fellow users, you’ll find actionable insights designed to elevate your work.
A Tool That Grows With You
Unlike static reports that offer just a snapshot in time, these Analytical Tools provide a full year of online access - complete with near real time updates, new features, pipeline alerts, and dedicated support. When you’re ready to go further, you can seamlessly renew your access or upgrade to the industry-leading full-service platform: 1stOncology - your comprehensive partner in oncology drug development.
System Requirements
- Web-based application compatible with all major browsers: Chrome, Firefox, Safari, and Internet Explorer
- Internet access
Secure Your Access to Unrivaled Intelligence for Strategic Decision-Making in Oncology Drug Development
This tool is powered by an award-winning, artificial intelligence (AI) enhanced intelligence platform with over 25 years of expertise in oncology, delivering uniquely comprehensive business, competitive and clinical intelligence across all stages of oncology drug development.
For business development and search & evaluation, it provides unmatched visibility into the global oncology landscape - spanning technologies, targets, start-ups to pharma, and academic-commercial opportunities - making it a powerful deal book with integrated licensing contacts and thousands of past deals.
In clinical development, the tool features an industry-leading biomarker intelligence panel of over 3,000 biomarkers and tracks their roles as stratifying, predictive, and pharmacodynamic markers, alongside companion diagnostic initiatives from early stage to approval. Proprietary early success/failure indicators spotlight clinical leaders and laggards, helping you monitor and and anticipate shifts in the evolving landscape.
This clinical trial intelligence goes beyond endpoints, capturing dosage details, resistance mechanisms, adverse events, food effects, trial phase and status progression, first-in-human (FIH) studies, tumor stage/grade, and line of therapy (LoT) - offering a complete view of the trial landscape.
The publisher simplifies the complexity of combination therapy development, breaking down targets, drug modalities, indications, and trial stages to create a map of evolving strategies for fast, strategic decision-making.
Finally, the team integrated Real-World Evidence (RWE) with multi-point analytics tailored to any development stage. Whether segmented by drug modality, co-medication profiles, or biomarker clusters, the tool enables deep, contextual insights - driving faster, smarter, and evidence-based decisions in oncology research and development.
Coverage Breakdown from your Oncolytic Virotherapies Analytical Tool
Competitor Overview
- Organizations Monitored: 270+
Organization Types:
- Corporate: 197
- Private: 121
- Public: 59
- Academic: 53
- Startup: 12
- Cancer Ctr/Hospital: 18
- Big Pharma/Biotech: 17
Top 5 Drug Developers:
- Transgene
- Virogin Biotech
- Akamis Bio
- Boeringer Ingelheim
- ImmVira
Top 5 Nations:
- USA
- China
- South Korea
- Germany
- Japan
Pipeline
- Total No Drugs: 360+
- Discovery: 50
- Preclinical: 220
- Phase 1: 49
- Phase 2: 38
- Phase 3: 8
- Pre-registration: 1
- Marketed: 2
- Target & Armor: 104
- Tumor Types: 102
- Clinical Trials: 293
- Clinical Biomarkers: 136
- Drugs in Combination Therapies: 50
Deals & Alliances
- No. Deals (Last 5 Years): 48
- BD&L Contacts: >400
- World-Wide Academic Commercial Opportunity Projects: 5
Funding & Investors
- Funding (Last 5 Years): >250
- Top Investors: 107
Companies Mentioned
- Transgene
- Virogin Biotech
- Akamis Bio
- Boeringer Ingelheim
- ImmVira
